# Phamacokinetics and Safety Profiles of DA-1229_01 2.5/500mg in Healthy Subjects at Fasting State

> **NCT05739851** · PHASE1 · UNKNOWN · sponsor: **Dong-A ST Co., Ltd.** · enrollment: 40 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** DA-1229_01 2.5/500mg (Before)
- **DRUG:** DA-1229_01 2.5/500mg (After)

## Key facts

- **NCT ID:** NCT05739851
- **Lead sponsor:** Dong-A ST Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-18
- **Primary completion:** 2023-04-14
- **Final completion:** 2023-04-14
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2023-02-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05739851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05739851, "Phamacokinetics and Safety Profiles of DA-1229_01 2.5/500mg in Healthy Subjects at Fasting State". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05739851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*